Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost?

• Zepbound KwikPen prices range from $299 to $449 per month, according to Eli Lilly.
• The company stated that in the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo.
• Among participants in the SURMOUNT-5 open-label study, those who took Zepbound lost an average of 20.2% of their body weight, or about 50 lbs.

Eli Lilly and Co. (LLY) on Monday announced a new version of its blockbuster weight-loss drug Zepbound, available in a KwikPen with a month’s supply.

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website. The new Zepbound KwikPen starts at $299 for the lowest dose.

Eli Lilly shares were up more than 4% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.

“As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities.

Source: Eli Lilly’s LillyDirect website

Lilly Touts Zepbound’s Efficacy

In its announcement, Lilly touted Zepbound's efficacy as the driver of demand for the weight-loss drug.

The company stated that in the SURMOUNT-1 trial, adults taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo.

Among participants in the SURMOUNT-5 open-label study, those who took Zepbound lost an average of 20.2% of their body weight, or about 50 lbs. In comparison, those who took Novo Nordisk AS’s (NVO) Wegovy reported 13.7% weight loss on average, or about 33 lbs, the company said.

Whom Can Zepbound Help?

Lilly stated in its announcement that Zepbound can help adults with obesity, or those who are overweight and also have weight-related medical problems.

The company added that Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

LLY stock is down 2% year-to-date, but up 20% over the past 12 months.

Also See: Why Is NVO Stock Falling Pre-Market Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on